Literature DB >> 34053079

Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden.

L Moyal1,2,3, C Arkin1,3, B Gorovitz-Haris1,2,3, C Querfeld4, S Rosen5,6, J Knaneh1,3, I Amitay-Laish2,3, H Prag-Naveh2,3, J Jacob-Hirsch7, E Hodak1,2,3.   

Abstract

BACKGROUND: Literature regarding exosomes as mediators in intercellular communication to promote progression in mycosis fungoides (MF) is lacking.
OBJECTIVES: To characterize MF-derived exosomes and their involvement in the disease.
METHODS: Exosomes were isolated by ultracentrifugation from cutaneous T-cell lymphoma (CTCL) cell lines, and from plasma of patients with MF and controls (healthy individuals). Exosomes were confirmed by electron microscopy, NanoSight and CD81 staining. Cell-line exosomes were profiled for microRNA array. Exosomal microRNA (exomiRNA) expression and uptake, and plasma-cell-free microRNA (cfmiRNA) were analysed by reverse-transcriptase quantitative polymerase chain reaction. Exosome uptake was monitored by fluorescent labelling and CD81 immunostaining. Migration was analysed by transwell migration assay.
RESULTS: MyLa- and MJ-derived exosomes had a distinctive microRNA signature with abundant microRNA (miR)-155 and miR-1246. Both microRNAs were delivered into target cells, but only exomiR-155 was tested, demonstrating a migratory effect on target cells. Plasma levels of cfmiR-1246 were significantly highest in combined plaque/tumour MF, followed by patch MF, and were lowest in controls (plaque/tumour > patch > healthy), while cfmiR-155 was upregulated only in plaque/tumour MF vs. controls. Specifically, exomiR-1246 (and not exomiR-155) was higher in plasma of plaque/tumour MF than in healthy controls. Plasma exosomes from MF but not from controls increased cell migration.
CONCLUSIONS: Our findings show that MF-derived exosomes promote cell motility and are enriched with miR-155, a well-known microRNA in MF, and miR-1246, not previously reported in MF. Based on their plasma expression we suggest that they may serve as potential biomarkers for tumour burden.
© 2021 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34053079      PMCID: PMC8864770          DOI: 10.1111/bjd.20519

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   11.113


  58 in total

1.  Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells.

Authors:  Ryan D Morin; Michael D O'Connor; Malachi Griffith; Florian Kuchenbauer; Allen Delaney; Anna-Liisa Prabhu; Yongjun Zhao; Helen McDonald; Thomas Zeng; Martin Hirst; Connie J Eaves; Marco A Marra
Journal:  Genome Res       Date:  2008-02-19       Impact factor: 9.043

Review 2.  Tumor-derived extracellular vesicles and microRNAs: Functional roles, diagnostic, prognostic and therapeutic options.

Authors:  Giada Pontecorvi; Maria Bellenghi; Rossella Puglisi; Alessandra Carè; Gianfranco Mattia
Journal:  Cytokine Growth Factor Rev       Date:  2019-12-31       Impact factor: 7.638

3.  Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides.

Authors:  Fuad Huaman Garaicoa; Alejandro Roisman; Mariana Arias; Carla Trila; Miguel Fridmanis; Alejandra Abeldaño; Silvia Vanzulli; Marina Narbaitz; Irma Slavutsky
Journal:  Tumour Biol       Date:  2016-07-29

4.  Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL).

Authors:  Ulrik Ralfkiaer; Peter H Hagedorn; Nannie Bangsgaard; Marianne B Løvendorf; Charlotte B Ahler; Lars Svensson; Katharina L Kopp; Marie T Vennegaard; Britt Lauenborg; John R Zibert; Thorbjørn Krejsgaard; Charlotte M Bonefeld; Rolf Søkilde; Lise M Gjerdrum; Tord Labuda; Anne-Merete Mathiesen; Kirsten Grønbæk; Mariusz A Wasik; Malgorzata Sokolowska-Wojdylo; Catherine Queille-Roussel; Robert Gniadecki; Elisabeth Ralfkiaer; Carsten Geisler; Thomas Litman; Anders Woetmann; Christian Glue; Mads A Røpke; Lone Skov; Niels Odum
Journal:  Blood       Date:  2011-08-24       Impact factor: 22.113

5.  Oncogenic role of microRNA-155 in mycosis fungoides: an in vitro and xenograft mouse model study.

Authors:  L Moyal; S Yehezkel; B Gorovitz; A Keren; A Gilhar; I Lubin; S Sherman; E Hodak
Journal:  Br J Dermatol       Date:  2017-05-07       Impact factor: 9.302

6.  miRNA expression profiling of mycosis fungoides.

Authors:  Marloes S van Kester; Erica Ballabio; Marchina F Benner; Xiao H Chen; Nigel J Saunders; Leslie van der Fits; Remco van Doorn; Maarten H Vermeer; Rein Willemze; Cornelis P Tensen; Charles H Lawrie
Journal:  Mol Oncol       Date:  2011-02-24       Impact factor: 6.603

7.  Cancer biomarker discovery and validation.

Authors:  Nicolas Goossens; Shigeki Nakagawa; Xiaochen Sun; Yujin Hoshida
Journal:  Transl Cancer Res       Date:  2015-06       Impact factor: 1.241

Review 8.  Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2017-10       Impact factor: 10.047

Review 9.  MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.

Authors:  Maria Gluud; Andreas Willerslev-Olsen; Lise Mette Rahbek Gjerdrum; Lise M Lindahl; Terkild B Buus; Mads Hald Andersen; Charlotte Menne Bonefeld; Thorbjorn Krejsgaard; Ivan V Litvinov; Lars Iversen; Jürgen C Becker; Jenny L Persson; Sergei B Koralov; Thomas Litman; Carsten Geisler; Anders Woetmann; Niels Odum
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

View more
  2 in total

Review 1.  The Role of microRNA in Pathogenesis, Diagnosis, Different Variants, Treatment and Prognosis of Mycosis Fungoides.

Authors:  Pengfei Wen; Yao Xie; Lin Wang
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

2.  Mycosis fungoides-derived exosomes and their microRNA-1246 cargo: a message from the skin.

Authors:  I Pospischil; E Guenova
Journal:  Br J Dermatol       Date:  2021-09-14       Impact factor: 11.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.